Mission of AABC

The mission of the Alzheimer’s Association® Business Consortium (AABC) is to advance Alzheimer’s disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer’s research and the goals of its member organizations. They provide leadership and direction to the group’s areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email Joseph Araujo or Dr. Codi Gharagouzloo co-chairs, or Dr. Christopher Weber, facilitator.

Welcome to our New Members

AABC is growing! Welcome to:

» Chris Kalafatis, Tom Sawyer, & Seyed-Mahdi Khaligh-Razavi, Cognetivity Neurosciences. Cognetivity is a MedTech spin-out from the University of Cambridge, UK. Its patented, artificial intelligence-based software, the Integrated Cognitive Assessment (ICA), provides an easy-to-use 5-minute sensitive, reliable and globally scalable test of cognitive ability. Delivered via touchscreen devices and the web, it allows early detection of cognitive issues, reducing time and cost of dementia diagnosis and care, leading to better outcomes for patients and reduced costs for healthcare systems. The ICA is an FDA Class II Medical Device and is reimbursable by insurance.

» Ornit Chiba-Falek & Boris Kantor CLAIRIgene, LLC. CLAIRIgene is a spinout startup from Duke committed to bringing gene-targeted epigenome therapies for unmet medical needs in CNS disorders with a focus on age-related neurodegenerative diseases. Our lead program in Alzheimer’s disease develops APOE-targeted epigenome therapy using CRISPR-Cas technology for specific repression of APOE e4 expression.

» Mark Collins & Dirk Smeets, icometrix. Founded in 2011, icometrix (Leuven, Belgium; Boston, USA) strives for data-driven insights and personalized patient care supported by artificial intelligence. icometrix offers a portfolio of eight regulatory approved AI solutions to assist healthcare with various challenges: icobrain extracts data from brain MRI and CT scans for the radiological reporting and clinical management of neurological disorders such as Alzheimer’s disease and related dementias, multiple sclerosis, traumatic brain injury, epilepsy, and stroke. icompanion, a digital platform and mobile app, helps people with neurological conditions and their care teams to monitor symptoms and treatments efficiently.

» Trevor Rajchgot, Christian Dansereau, & Adrian Noriega, Perceiv AI. Perceiv AI is an AI-driven precision medicine company developing a powerful multimodal prognostic platform to forecast disease progression across the Alzheimer’s spectrum. By providing a window into the disease progression of individual patients, Perceiv AI aims to accelerate and de-risk the development of new therapies while enabling timelier diagnoses. For more information, please visit perceiv.ai.

» James Hamet & Cris Micheli, Vistim Labs Inc. Vistim is developing an artificial intelligence platform that learns from brain activity and correlates this activity with biomarkers of cognitive decline. They seek to prove prognostic utility that might a) shorten the time to diagnosis within the patient pathway, and b) provide a measure of treatment efficacy which reflects patients’ individual longitudinal disease progression and measurable differences caused by therapeutic interventions. They aim to realize these goals by detecting the earliest signs of cognitive decline ahead of other biomarkers such as amyloid load as detected via positron emission tomography, blood, or other bodily fluids.
**Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson’s Disease**

*FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson’s Disease*

**Annovis Bio, Inc.** (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) with regard to the company’s planned Phase 3 clinical studies of Buntanetap for the treatment of Parkinson’s disease (PD) as an offshoot of the company’s clinical program in Alzheimer’s disease (AD).

Following the company’s submission of the Phase 2 clinical data and the chronic toxicology data in animals, the company requested directions to further pursue the development of Buntanetap in PD. The FDA provided guidance on the initiation of the Phase 3 clinical studies of Buntanetap for PD in parallel with the AD program. The agency detailed guidance on the specific endpoints, entry criteria, and further study parameters for two Phase 3 studies that would support a broad indication for both early and late PD.

“We appreciate the thoughtful and clear feedback from the FDA regarding our clinical program, and we are thrilled with the acceptance of our proposed development plan for Buntanetap in Parkinson’s disease,” said Maria L. Maccecchini, Ph.D., founder, president, and CEO of Annovis Bio. “Now we can continue with all necessary steps to begin the Phase 3 trials in PD.”

Additionally, the FDA provided guidance on updating the existing Investigational New Drug Application (IND) for AD based on the result of the successful Phase 2 study and in preparation for an End of Phase 2 meeting on the AD indication.

**icometrix Updates:**

- AI plays an important role in the diagnosis and follow-up of dementia. icometrix Medical Advisory Board members Suzie Bash, M.D., and Lawrence N Tanenbaum, M.D., FACR recently published an article for Applied Radiology on the hopeful role of Imaging AI in the fight against Alzheimer’s, mentioning our latest aria reports.

- icometrix was selected as a new data partner in the European Health Data and Evidence Network project (EHDEN), a public-private partnership set up under the framework of the IMI2 program. This was launched to address the current challenges in generating insights and evidence from real-world clinical data at scale.

- ALZimaging.com, the independent and free e-learning platform which offers educational content about Alzheimer’s disease and its relationship with neuro-imaging techniques for diagnosis, management, and safety reading, was launched. The platform currently includes five chapters, curated content by renowned experts, quizzes, access to four CME-accredited webinars, and panel discussion videos.

**712 North Inc. announces publication of a review article in Pharmacological Research**

712 North Inc., a California-based pharmaceutical company, announced on January 13, 2022 publication of the overview article “Recent advances in, and challenges of, designing OMA1 drug screens” in Pharmacological Research.

712 North Inc. spearheads personalized mitochondrial medicines for individuals with Alzheimer’s and other aging-related diseases by developing OMA1 protease inhibitors. Dr. Alavi discusses the different approaches to develop OMA1 drug screens in this comprehensive review article and shares some of his insights into the biology.

For more information, please visit [712north.com](http://712north.com).
Funding Secured for Preclinical Trials

Septa Therapeutics Inc. is a biotechnology company devoted exclusively to a new approach in the development of a therapeutic to treat Alzheimer’s disease (AD). We are pleased to announce that funding in the amount of $350,000 has been secured to conduct preclinical trials for our new drug candidate.

The company believes that it has identified the “trigger” that initiates events leading to AD pathology. Specifically, we have patented an activity associated with amyloid beta which may lead to the inflammation characteristic of AD. Our new drug candidate is designed to block this inflammation. Our approach is new. While other studies have attempted to remove amyloid beta, we will leave the amyloid in place, while inhibiting its inflammatory activity. Our progress may be monitored at SeptaTherapeutics.com.

New collaboration between Unlearn.AI and Merck KGaA

Unlearn.AI announced a multi-year collaboration with Merck KGaA, Darmstadt, Germany to accelerate late-stage clinical trials with novel trial designs that include Digital Twins. This collaboration will focus on advancing the regulatory approval of candidates in Merck KGaA, Darmstadt, Germany’s immunology pipeline, with the potential to expand into other therapeutic areas. Read the press release here.

Watch Unlearn.AI's latest on-demand webinar, “Using external data to accelerate randomized controlled trials without introducing bias.” Charles Fisher, founder and CEO, and Dave Miller, chief scientific officer, discuss how novel, AI-driven trial designs accelerate RCTs and provide reliable evidence suitable for supporting regulatory decisions.

Unlearn.AI is hiring! Unlearn is the only company creating Twintelligent RCTs™, which combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient clinical trials. Visit Unlearn.AI’s careers page to learn more.

Unlearn.AI founder and CEO Charles Fisher will be speaking on the Partnering with Pharma on Digital Biomarkers, Diagnostics & Therapeutics Panel at the virtual 5th Annual Sachs Neuroscience Innovation Forum, March 22-23, 2022. Fisher will also be presenting a Spotlight Showcase (on-demand) to discuss how Twintelligent RCTs™ enable smaller, more efficient clinical trials.

QMENTA releases a portfolio of Artificial Intelligence tools to help clinical studies into Alzheimers and other Brain Diseases

Massachusetts based QMENTA Inc has released a new portfolio of Artificial Intelligence (AI) tools for the comprehensive analysis of medical images for brain diseases, including Alzheimers disease, dementia, multiple sclerosis, neuropsychiatric and neurooncology. QMENTA’s AI Imaging Disease Packages give experts conducting research and clinical trials access to the latest AI tools to analyze disease progress and the effects of new therapies. Among other factors, these smart tools measure changes to the structure of the brain including volume, amyloid plaque, Tau tangles, white matter and connectivity, all in a single imaging management solution.

Learn more:
AI Imaging Disease Packages
Dementia & Alzheimer’s Disease

Upcoming Events

Register today for Latinos & Alzheimer’s Symposium

Date: April 25-26, 2022
Location: Hyatt Regency Coconut Point Resort and Spa in Bonita Springs, Florida and online

Now in its third year, the Latinos & Alzheimer’s Symposium will address updates to research and practice knowledge in order to better inform the care of Latino/Hispanic individuals living with dementia and their families.

Register now for opportunities to network, receive mentoring, and collaborate with researchers and health care professionals.
Register today for Neuro4D Conference May 16-17, 2022

The Neuro4D is an international conference on Neuro Degenerative Disease Drug Discovery bringing together drug discovery companies, service and technology providers, and academic innovators in the field of proteopathic neurodegenerative diseases in a highly interactive format.

The conference differentiates itself by bringing together distinguished industry and academic speakers specialized in neurodegenerative disease drug discovery in direct contact and lively discussions. Academic research leaders outline recent findings and insights into the complicated disease mechanisms. Biotech and international pharmaceutical drug discovery companies will present their most recent achievements to develop new treatment options and outline the models and technologies used in compound selection and optimization. Service and technology companies will present their platforms and show examples of how their services contribute to the discovery of new drug candidates.

Attend AAIC 2022 in San Diego or online

Join the global dementia research community at the Alzheimer’s Association International Conference® 2022 (AAIC®), July 31-Aug. 4 in San Diego, USA or online. Attend AAIC to share, network and collaborate with basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science.

Early bird registration rates end May 13.

Register today and save.

Social Media

Join our new LinkedIn page! As discussed during the AABC meeting at the Alzheimer’s Association International Conference®, please visit our page and request to join. We look forward to using the page to foster partnerships and communications.

Alzheimer’s Association Science Hub App

Science Hub provides the latest news right in the palm of your hand. This trusted tool distributes research, spreads awareness and delivers accurate information directly to your phone.

Learn more at alz.org/sciencehub, or search “Science Hub” in your app store.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen.